Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
出版年份 2022 全文链接
标题
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
作者
关键词
-
出版物
JAMA Oncology
Volume 8, Issue 4, Pages 597
出版商
American Medical Association (AMA)
发表日期
2022-02-25
DOI
10.1001/jamaoncol.2021.8049
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer
- (2021) Boshen Jiao et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
- (2021) Li-Jen Cheng et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.
- (2021) Federico Manevy et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics
- (2020) Cameron M. Phillips et al. CANCER
- Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
- (2020) Kelvin Chan et al. BMJ Open
- Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
- (2020) Wei Fang Dai et al. BMC CANCER
- Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes
- (2020) Inna Y. Gong et al. BREAST CANCER RESEARCH AND TREATMENT
- Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients
- (2020) Thomas Christensen et al. BREAST
- Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time
- (2018) Ronak Saluja et al. Journal of Oncology Practice
- The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)
- (2018) Sinéad M Langan et al. BMJ-British Medical Journal
- Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer
- (2017) Henry W. C. Leung et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Phase-specific and lifetime costs of cancer care in Ontario, Canada
- (2016) Claire de Oliveira et al. BMC CANCER
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2016) Ben Y. Durkee et al. JOURNAL OF CLINICAL ONCOLOGY
- Unknown
- (2015) CLINICAL PHARMACOLOGY & THERAPEUTICS
- Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters
- (2015) Wanrudee Isaranuwatchai et al. PHARMACOECONOMICS
- Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
- (2014) Nigel Fleeman et al. PHARMACOECONOMICS
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force
- (2013) Louis P. Garrison et al. VALUE IN HEALTH
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
- (2011) Peter C. Austin MULTIVARIATE BEHAVIORAL RESEARCH
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
- (2009) Peter C. Austin STATISTICS IN MEDICINE
- Interpreting the Results of Cost-Effectiveness Studies
- (2008) David J. Cohen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started